Evidence map›Paper›PMID 41980230›Full record

Observational studyNeurology2026

Influence of Decreased Kidney Function on Plasma Biomarkers of Neurodegenerative Disorders in Routine Care: Confirmation of the Interest of Ratios.

Etienne Mondésert, Jean-Paul Cristol, Anne-Sophie Bargnoux, Marie Duchiron, Germain Ulysse Busto, Christophe Hirtz, Geneviève Barnier-Figue, Florence Perrein, Cédric Turpinat, Snejana Jurici and 4 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05427448 (Clinical Validation of the Use of Blood Biomarkers for the Diagnosis and Monitoring of Alzheimer's Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05427448 nacompletednot on this map

Clinical Validation of the Use of Blood Biomarkers for the Diagnosis and Monitoring of Alzheimer's Disease

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2022 to 2025Enrolled342ConditionsAlzheimer Disease, Mild Cognitive Impairment, Dementia, TauopathiesArmsMeasurement of amyloid and pTau blood biomarkers
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Chronic kidney disease and cognitive decline: choroid plexus remodeling, glymphatic dysfunction, and alzheimer biomarker interpretation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Etienne MondésertLBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, France.ORCID 0009-0003-3235-3740
Jean-Paul CristolDepartment of Biochemistry and Hormonology, University Hospital Center of Montpellier, France.ORCID 0000-0001-8563-7278
Anne-Sophie BargnouxDepartment of Biochemistry and Hormonology, University Hospital Center of Montpellier, France.
Marie DuchironLBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, France.ORCID 0009-0008-5122-5070
Germain Ulysse BustoCMRR, CHU de Montpellier, France.ORCID 0000-0002-8787-563X
Christophe HirtzLBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, France.ORCID 0000-0002-7313-0629
Geneviève Barnier-FigueCentre de Mémoire Territorial Gériatrie, CH de Perpignan, France.ORCID 0009-0006-6267-2525
Florence PerreinDépartement de Neurologie, CHU de Nîmes, France; and.
Cédric TurpinatCMRR, CHU de Montpellier, France.
Snejana JuriciCentre de Mémoire Territorial Gériatrie, CH de Perpignan, France.ORCID 0000-0001-5241-0261
Audrey GabelleCMRR, CHU de Montpellier, France.ORCID 0000-0002-7648-9194
Karim BennysCMRR, CHU de Montpellier, France.ORCID 0000-0003-1363-0143
Sylvain LehmannLBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, France.ORCID 0000-0001-6117-562X
Constance DelabyLBPC-PPC, Université de Montpellier, INM INSERM, IRMB CHU de Montpellier, France.ORCID 0000-0002-8606-6814

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesInterest in plasma biomarkers for neurodegenerative disorders is growing, but their reliance on glomerular filtration makes kidney function a key potential confounder. This study assesses the effect of kidney function (eGFR) on plasma biomarkers of neurodegeneration and on their accuracy for detecting cerebral amyloidosis.

methodsThis observational study aims at studying the effect of kidney function on blood biomarkers through simultaneous measurements of creatinine, plasma, and CSF biomarkers (Aβ42, Aβ40, p-tau181, p-tau217, neurofilament light chain [NfL], glial fibrillary acidic protein [GFAP], and brain-derived tau [BD-tau]), as well as plasma biomarker ratios (Aβ42/Aβ40, p-tau217/Aβ42, NfL/p-tau217, and p-tau181/Aβ42), in the ALZAN cohort of patients. This prospective multicenter cohort (#NCT05427448), recruited across Montpellier, Nîmes, and Perpignan hospitals, included patients from November 2022 to July 2024 who met the following criteria: age ≥18 years, informed consent, and concomitant CSF and blood sampling. To determine the association between plasma biomarkers and kidney function, we performed univariable linear regression analyses.

resultsA total of 420 patients were included (mean age: 71.1 years, %female: 53.2) and subdivided into 3 groups according to eGFR value (ml/minute/1.73 m DISCUSSION: Impaired kidney function was linked to increased plasma cerebral amyloidosis biomarkers, but ratio-based measures (especially p-tau217/Aβ42) showed stable sensitivity and specificity for detecting cerebral amyloidosis across all eGFR groups. Additional studies including more patients with lower eGFR values in diverse diagnostic settings are needed to clarify the influence of kidney function on these biomarkers. CLASSIFICATION OF EVIDENCE: This Class II evidence shows that kidney function influences individual blood biomarkers used for cerebral amyloidosis detection, but not their ratios. TRIAL REGISTRATION INFORMATION: NCT05427448.

Indexed as

Neurodegenerative DiseasesAgedAmyloid beta-PeptidesBiomarkersCreatinineFemaleGlial Fibrillary Acidic ProteinGlomerular Filtration RateHumansMaleMiddle AgedNeurofilament ProteinsProspective Studiestau ProteinsAmyloid beta-PeptidesBiomarkersCreatinineGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinstau Proteins

Identifiers

PMID41980230
PMCPMC13089192

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.